- Home
- SPKL vs PBYI Comparison
SPKL vs PBYI Comparison
Compare SPKL & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SPKL
- PBYI
- Stock Information
- Founded
- SPKL 2021
- PBYI 2010
- Country
- SPKL United States
- PBYI United States
- Employees
- SPKL N/A
- PBYI N/A
- Industry
- SPKL
- PBYI Biotechnology: Pharmaceutical Preparations
- Sector
- SPKL
- PBYI Health Care
- Exchange
- SPKL Nasdaq
- PBYI Nasdaq
- Market Cap
- SPKL 174.6M
- PBYI 153.2M
- IPO Year
- SPKL 2023
- PBYI N/A
- Fundamental
- Price
- SPKL $10.66
- PBYI $3.09
- Analyst Decision
- SPKL
- PBYI Strong Buy
- Analyst Count
- SPKL 0
- PBYI 1
- Target Price
- SPKL N/A
- PBYI $7.00
- AVG Volume (30 Days)
- SPKL 44.7K
- PBYI 754.5K
- Earning Date
- SPKL 01-01-0001
- PBYI 02-27-2025
- Dividend Yield
- SPKL N/A
- PBYI N/A
- EPS Growth
- SPKL N/A
- PBYI 492.79
- EPS
- SPKL 0.19
- PBYI 0.47
- Revenue
- SPKL N/A
- PBYI $243,569,000.00
- Revenue This Year
- SPKL N/A
- PBYI N/A
- Revenue Next Year
- SPKL N/A
- PBYI N/A
- P/E Ratio
- SPKL $57.45
- PBYI $6.63
- Revenue Growth
- SPKL N/A
- PBYI 6.30
- 52 Week Low
- SPKL $10.18
- PBYI $2.23
- 52 Week High
- SPKL $11.95
- PBYI $7.73
- Technical
- Relative Strength Index (RSI)
- SPKL 61.06
- PBYI 49.17
- Support Level
- SPKL $10.63
- PBYI $2.92
- Resistance Level
- SPKL $10.66
- PBYI $4.06
- Average True Range (ATR)
- SPKL 0.02
- PBYI 0.29
- MACD
- SPKL 0.00
- PBYI 0.01
- Stochastic Oscillator
- SPKL 75.00
- PBYI 27.07
About SPKL Spark I Acquisition Corp.
Spark I Acquisition Corp is a Blank check company.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes innovative products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis leading to apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.